In 2004 and September 2005 December, we announced positive top-line outcomes for the second and first pivotal Stage 3 atrial fibrillation trials, or Action 1 and ACT 3, respectively. Furthermore, positive top-line outcomes from ACT 2, evaluating KYNAPID for the treatment of atrial fibrillation pursuing cardiac surgery, in June 2007 were announced. Astellas also carried out an open-label safety study, or ACT 4, to be able to gather additional basic safety data. The NDA for KYNAPID was submitted in December 2006. In December 2007, the FDA Cardiovascular and Renal Medicines Advisory Committee suggested to the FDA that KYNAPID be approved for rapid transformation of acute atrial fibrillation to sinus rhythm. In August 2008, Astellas received an Approvable letter from the FDA..Associated Press.
CblF and ABCD4 proteins responsible for hereditary vitamin B12 deficiency Supplement B12 is essential for cell division, the synthesis of red blood cells and the functioning of the nervous system. Unable to produce the supplement itself, the body must obtain it via pet proteins. So far it’s been known that on its way into the cell supplement B12 can be absorbed by small organelles, so-called lysosomes. From there, the vitamin enters the cell interior using the transport protein CblF, which was uncovered by the same research team 3 years ago. The researchers right now show a second transport protein is necessary for this step actually, thus providing evidence of another cause of hereditary vitamin B12 deficiency. Gene mutation stops transport of vitamin B12 Related StoriesVitamin D insufficiency puts people at risk of developing heart problemsFindings support higher dietary requirements of supplement E for obese people with metabolic syndromeUse of dicloxacillin associated with INR decrease in patients taking supplement K antagonistsThe scientists in Switzerland and Canada each examined a person individual with symptoms of the CblF gene defect, however without an real defect in this gene.